D. et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 15, e42–e50 (2014). Article CAS PubMed PubMed Central Google Scholar Felip, E. et al. ...
Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535-546.Z. Chen, C. M. Fillmore, P. S. Hammerman, C. F. Kim, and K.- K. Wong, "Non-small-cell lung cancers: a heterogeneous set of diseases," Nature Reviews Cancer, vol. 14, no. 8...
Non-Small Cell Lung Cancer (NSCLC) Adverse Effects Biomarkers Brain Cancer Breast CancerBreast CancerBreast Cancer Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary ...
网络非小型细胞肺癌 网络释义 1. 非小型细胞肺癌 非小型细胞肺癌(non-small-cell lung cancers)的情形下,循环中的TGF-β浓度已被证实和对治疗的反应相关。 blog.sina.com.tw|基于9个网页
1.The other 75 per cent of lung cancers consist of a variety of "non-small cell cancers".其余75%的肺癌属于各种“非小细胞肺癌”。 2.hsa-miR-125a-5p Enhances Invasion Ability in Non-Small Lung Carcinoma Cell Lineshsa-miR-125a-5p促进非小细胞肺癌细胞侵袭 3.Gifitinib in the Treatment for...
Large-cell (undifferentiated) carcinoma: This fast-growing cancer can be in any part of the lung. Because it spreads quickly, it can be harder to treat. About 10% of non-small-cell lung cancers are this type. Causes Most lung cancers are linked to smoking. Many people who get lung canc...
7.The other 75 per cent of lung cancers consist of a variety of "non-small cell cancers".其余75%的肺癌属于各种“非小细胞肺癌”。 8.hsa-miR-125a-5p Enhances Invasion Ability in Non-Small Lung Carcinoma Cell Lineshsa-miR-125a-5p促进非小细胞肺癌细胞侵袭 9.Gifitinib in the Treatment for...
Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have diverse pathological features. During the past decade, in-depth analyses of lung cancer genomes and signalling pathways have further defined NSCLCs as a group of distinct diseases with genetic and cellular het...
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases which accounts for 80% of newly diagnosed lung cancers. In the previous decade, a new molecular subset of NSCLC patients (around 2%) harboring rearrangements of thec-ros oncogene 1was defined.ROS1+ NSCLC is typically dia...
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther Published on-line August 14, 2012." NSCL-16 · Continuation maintenance chemotherapy: > Bevacizumab + pemetrexed added with category 2A recommendation ...